|
|
|
|
|
|
|
Synthetic Biologics- Inc. (SYN)
|
|
0.204 -0.008 (-3.77%)
|
07-19 16:00
|
|
Open:
|
0.213
|
Pre. Close:
|
0.212
|
|
High:
|
0.2188
|
Low:
|
0.2022
|
|
Volume:
|
229,765
|
Market Cap:
|
26M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
0.22 - 0.222
|
0.222 - 0.223
|
|
Low:
|
0.197 - 0.199
|
0.199 - 0.2
|
|
Close:
|
0.208 - 0.21
|
0.21 - 0.212
|
|
|
|
Technical analysis (as of: 2018-07-19 4:33:15 PM)
|
|
Overall:
|
|
|
Stoxline posted a NEUTRAL today, same as yesterday. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next Buy or SELL signal.
|
|
Target:
|
Six months: 0.28 One year: 0.30
|
|
Support:
|
Support1: 0.20 Support2: 0.17
|
|
Resistance:
|
Resistance1:
0.24 Resistance2: 0.26
|
|
Pivot:
|
0.22 
|
|
Moving Averages:
|
MA(5): 0.21 MA(20): 0.22
MA(100): 0.28 MA(250): 0.50
|
|
MACD:
|
MACD(12,26):
-0.01  Signal(12,26,9): -0.01
|
|
%K %D:
|
%K(14,3): 18.28 %D(3): 19.06
|
|
RSI:
|
RSI(14): 43.61
|
|
52-Week:
|
High: 1.05
Low: 0.19 Change(%): -59.1
|
|
Average Vol(K):
|
3-Month: 61135
10-Days 48575
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.SYN has closed above bottom band by 31.8%. Bollinger Bands are 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to SYN's normal range. The bands have been in this narrow range for 45 bars. This is a sign that the market may be about to initiate a new trend.
|
|
|
Headline News
|
|
2018-05-22T07:00:00-04:00
Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American
2018-05-08T21:37:06-04:00
Synthetic Biologics' (SYN) Management on Q1 2018 Results - Earnings Call Transcript
2018-05-08T16:05:00-04:00
Synthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial Results
2018-04-26T07:00:00-04:00
Synthetic Biologics to Report First Quarter 2018 Operational Highlights and Financial Results on May 8, 2018
2018-04-24T03:11:01-04:00
Biotech Analysis Central Pharma News: Synthetic Loses Designation, Sage Files NDA , Alnylam Gets Positive Opinion From EMA
2018-04-23T07:00:00-04:00
Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection
2018-03-09T13:19:31-05:00
Homology Medicines Files For U.S. IPO
2018-03-07T16:10:00-05:00
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
NA
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
